title: Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant             adeno-associated virus serotype 2 carrying interleukin-15 in mice.
abstract: Human interleukin-15 (hIL15) exerts anticancer effects through the activities             of lymphokine-activated killer (LAK) cells. However, its short half-life hinders             its clinical application. Recombinant adeno-associated virus serotype 2 (rAAV2)             is used for hIL15 gene transfer vectors, because of its low immunogenicity and             long-term gene expression in human clinical trials. SV40 T/t antigens are related             with many human epithelial cancers and are generally found in human breast cancer.             In order to demonstrate the anticancer effects of hIL15 on SV40 T/t antigen-induced             breast cancer, rAAV2-hIL15 was constructed and an SV40 T/t antigen-induced transgenic             mouse breast cancer model was established. Our study showed that rAAV2-hIL15 could             express the hIL15 protein with anticancer bioactivity. In addition, rAAV2-hIL15             could activate the cytotoxic activity of LAK cells in vivo. Furthermore, the rAAV2-hIL15             successfully delayed cancer growth and eventually led to cancer cell death in             SV40 T/t antigen-induced breast cancer transgenic mice. In summary, our study             indicates that rAAV2-hIL15 may be applied for cancer immunotherapy of SV40 T/t             antigen-induced breast cancer.
authors.affiliation: Department of Emergency Medicine, Buddhist Tzu Chi University,                     Hualien, Taiwan, R.O.C.
authors.forename: Giou-Teng
authors.initials: GT
authors.lastname: Yiang
authors.forename: Pei-Lun
authors.initials: PL
authors.lastname: Chou
authors.forename: Hsiu-Feng
authors.initials: HF
authors.lastname: Tsai
authors.forename: Li-Ann
authors.initials: LA
authors.lastname: Chen
authors.forename: Wei-Jung
authors.initials: WJ
authors.lastname: Chang
authors.forename: Yung-Luen
authors.initials: YL
authors.lastname: Yu
authors.forename: Chyou-Wei
authors.initials: CW
authors.lastname: Wei
mesh_terms: D000818:Animals; D000952:Antigens, Polyomavirus Transforming / Q000276:immunology*; D001940:Breast / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D001943:Breast Neoplasms / Q000235:genetics / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D002460:Cell Line; D045744:Cell Line, Tumor; D000229:Dependovirus / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D007167:Immunotherapy; D019409:Interleukin-15 / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D051379:Mice; D008822:Mice, Transgenic
chemical_list: D000952:Antigens, Polyomavirus Transforming; D019409:Interleukin-15